A Phase 4 interventional study of Vaccine in Safety, Immunogenicity, Vaccine and COVID-19 Vaccines, sponsored by Centers for Disease Control and Prevention, China. Status unknown at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Centers for Disease Control and Prevention, China · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.
Among the 173 studies in Influenza, Human with a site in China, this one is the 14th largest by planned enrollment of the 157 interventional ones that give a count, is one of 13 that started in 2021, is one of 43 in phase 4, and was the 107th registered.
2,358 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 6 mo+ · Healthy volunteers
Shanghai Institute Of Biological Products · Sites in China
Ages 60+ · Healthy volunteers
Capital Medical University · Sites in China
Ages 12+
Ruijin Hospital · Sites in China
Ages 12–17
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 120 Influenza, Human studies recruiting now, 64 (53%) set no upper age limit and 46 (38%) stop at 75 or younger; 33 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 22 · Phase 3 49 · Phase 4 43
First in 2004; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 360 across the 157 interventional studies, 230 across the 14 observational. Of the 115 that completed or were terminated, 9 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 173 have an industry lead sponsor. The 10 most frequent:
Centers for Disease Control and Prevention, China is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
Centers for Disease Control and Prevention, China has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
14 of the studies in Influenza, Human with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229547Phase 3Ruijin HospitalA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A. | 2026-12-01 |
| NCT07236814Phase 3Capital Medical UniversitySuraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting | 2027-03-01 |
| NCT07893847Phase 3Capital Medical UniversityEvaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza | 2027-03-30 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06574503Phase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | 2027-07-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 173 studies in Influenza, Human with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide vaccine in people aged 18 years and older. A randomized controlled, open trial design was adopted.
The study was conducted with informed consent of the subjects for immunogenicity and safety in the population aged 18 years and older. A total of 3000 healthy subjects were selected, (1)600 healthy subjects were selected for the immunogenicity and safety study of co-immunization, 300 in the adult group (18-59 years old) and 300 in the elderly group (60 years old and above); (2) 2400 healthy subjects were selected for the observational study of the safety of co-immunization, 1200 in the adult group (18-59 years old) and 1200 in the elderly group (60 years old and above ) 1200 people.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Vaccine
Biological: Vaccine
Biological: Vaccine
Different arms were administrated different vaccines
Seroconversion rate of neutralizing antibody
Time frame: 28 days after the third dose of COVID-19 vaccine
Started Oct 2021 (actual). Primary completion is estimated for Dec 2022, 14 months after the start.
Of 101 non-industry phase 4 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's planned 14 months is below that.
Counting every sponsor, half of 137 studies reached it within 14 months; a quarter within 3 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centers for Disease Control and Prevention, China